What Algesal suractive treats: main uses and benefits

The therapeutic application is primarily focused on providing symptomatic relief for localized rheumatic and minor musculoskeletal conditions, particularly in contexts marked by increased discomfort or tension across several therapeutic domains.

It is commonly used across conditions presenting with acute episodes, helping to manage localized pain, inflammation, and associated swelling. Specifically, it may be part of symptomatic management for minor physical trauma, including muscle strains, ligament sprains, and bruises, and for regional aches like lumbago, fibrositis, and presentations of sciatica.

The combination provides support that helps ease the overall symptom burden and addresses both the acute discomfort and the related inflammatory symptoms. This may assist patients in coping more steadily with symptom fluctuations.

Quick Fact: Relief for Localized Pain
Primary Focus	Musculo-skeletal and Soft Tissue Pain
Target Symptoms	Pain, Inflammation, Muscular Tension
Typical Use	Minor Acute Injuries (Sprains, Strains)
Patient Benefit	Contributes to Improved Day-to-Day Comfort

Eligibility Map: Who can and cannot use Algesal suractive — Official Regulatory Information

The eligibility profile for this combination topical medicine is strictly defined by regulatory contraindications and age-group restrictions, primarily due to the presence of a salicylate derivative (NSAID) and terpene excipients.

Category	Regulatory Statement
Populations for whom use is allowed	Adults and children aged 6 years and over are the populations for whom use is indicated and posology is defined [1.2].
Populations for whom use is contraindicated	Individuals with known hypersensitivity to Diethylamine Salicylate, Myrtecaine, or any excipients [1.1]. Patients with known allergy to aspirin or other NSAIDs (non-steroidal anti-inflammatory drugs) [1.1]. Infants and children under 2 years of age (risk of laryngospasm) [1.1]. Children who have a history of convulsions (seizure disorders) [1.1]. Use on broken skin, eczematous, or inflamed skin [1.1].
Age-related eligibility rules	Children under 6 years of age are generally not recommended to use the product [1.2].
Condition-specific eligibility rules	Contraindicated in patients with bronchial asthma or other respiratory diseases associated with marked hypersensitivity of the airways [1.1].
Pregnancy and lactation eligibility status	Pregnancy: Use should not be used unless there is no safer alternative, particularly during the last three months [1.1]. Lactation: Use is not recommended [1.2].

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated (Absolute non-eligibility) for hypersensitivity, specific pediatric, and skin conditions [1.1]. Not Recommended (Restriction/Avoidance) for children under 6 and during lactation [1.2].

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use this medicine primarily through a list of absolute contraindications based on patient hypersensitivity and specific medical/age-related risks. Eligibility is further restricted by explicit avoidance statements for certain age groups and physiological states.

The potential for this product to interact with other medicines arises from the systemic absorption of the salicylate component, which is similar to other non-steroidal anti-inflammatory drugs (NSAIDs). Significant drug interactions are typically considered possible in rare cases, primarily when the cream is used in repeated, prolonged, or large-area applications.

Documented Interacting Medicines and Classes

The following medications or drug classes have documented interaction potential:

• Coumarin Anticoagulants: Topical salicylates, such as the one in this cream, may potentiate the effect of oral anticoagulants like warfarin, increasing the risk of bleeding. Caution is advised for patients taking these blood-thinning medicines.
• Methotrexate: Salicylates may increase the blood levels and potential toxicity of methotrexate by delaying its removal from the body. This interaction is usually associated with higher systemic salicylate exposure.
• Oral Antidiabetics: Concurrent use of this cream over large areas may rarely affect the action of medicines taken by mouth to lower blood sugar.
• Other NSAIDs and Corticoids: Using this cream alongside other non-steroidal anti-inflammatory drugs may increase the risk of side effects. Simultaneous use with corticoids may be associated with an increased risk of gastrointestinal bleeding or water retention.
• Diuretics: Interactions are possible with certain medicines that promote urination and salt excretion, such as Spironolactone.

Interaction-Related Monitoring

For patients taking coumarin derivatives (anticoagulants) or oral antidiabetics, specific monitoring of prothrombin time (a blood clotting test) or blood sugar is recommended if the cream is used for prolonged periods over large skin areas.

Algesal suractive is a non-steroidal anti-inflammatory drug (NSAID) that functions primarily as a selective cyclooxygenase-2 ( COX-2) inhibitor. This compound exhibits a preferential affinity for the COX-2 isoenzyme over the COX-1 isoenzyme. The core action involves the reversible competitive inhibition of COX-2 by binding to its active site.

The COX-2 enzyme is responsible for the conversion of arachidonic acid into various prostanoids. By blocking this enzymatic step, Algesal suractive significantly reduces the synthesis of pro-inflammatory mediators, particularly prostaglandin E2 ( PGE2). The subsequent system-level physiological consequence is the localized reduction of PGE2 concentration in affected tissues, which modulates local microvasculature permeability and restricts downstream inflammatory signaling cascades. This mechanism focuses strictly on altering the molecular pathway and resulting physiological effects.

Algesal suractive is used exclusively via the cutaneous route, meaning it is formulated only for external, topical application to the skin. The administration method involves applying a descriptive dose, typically defined as a small amount of the cream or ointment sufficient to cover the localized affected area.

The standard frequency of application is high, with instructions specifying use up to three times daily. This multiple-times-daily schedule defines the required regimen for proper utilization.

Procedural Instructions

For effective application, the preparation must be massaged thoroughly into the skin until it is fully absorbed. This step ensures appropriate delivery of the active components. Following the completion of the application, it is necessary to wash hands well immediately after use to prevent contact with sensitive areas.

Usage is strictly intended for short-term duration only, and treatment should not be prolonged beyond the maximum period specified (e.g., typically 7 days) without professional guidance.

Administration Summary

High-Level Administration Principles	Official Guideline
Route & Frequency	Applied cutaneously, up to three times per day.
Dosing Pattern	A small amount, massaged until fully absorbed.
Age Restriction	Not recommended for children under 6 years of age.

This structured approach defines the precise procedural requirements for using the topical analgesic.

Algesal suractive: Recent Clinical Evidence

The research evidence for this preparation is primarily derived from studies of its topical salicylate component. These controlled trials were designed to explore short-term changes in symptoms in defined adult populations.

Evidence for Use in Localized Acute Musculoskeletal Conditions

Research has examined the use of topical salicylate preparations in adults presenting with localized acute musculoskeletal conditions such as minor muscle strains and sprains. These studies were mainly short-term randomized controlled trials (RCTs) where patient-reported outcomes describing perceived discomfort were monitored. Findings from early trials described differences in the patterns of reported discomfort compared to a non-active cream. However, evidence quality varies across studies, and the follow-up durations were limited, typically lasting around seven to ten days.

Evidence for Use in Localized Chronic Musculoskeletal Pain

Studies exploring the use of topical salicylates in conditions characterized by fluctuating or episodic manifestations of chronic pain have shown mixed results. Research in this area is generally associated with lower certainty. While short-term trials monitored discomfort outcomes, some of the larger studies found that measured outcomes between the active topical salicylate and the non-active control were not different in chronic settings.

Research Gaps and Uncertainty

The majority of studies focused on short-term symptom changes, and long-term effects are not fully established. Data for certain groups remain insufficient, as the trials primarily focused on general adult cohorts. There is limited information available for older adults or those with multiple existing conditions. Overall, comparative evidence is lacking for many specific salicylate derivatives, and the low certainty that remains highlights where further research is needed.

Common questions about Algesal suractive (FAQ)

Q: Is Algesal suractive available over-the-counter?

Yes. According to official documents, Algesal suractive is classified as an Over-the-Counter (OTC) medicine. This means it is available without needing a prescription from a doctor and is indicated for local, symptomatic relief.

---

Q: What is the difference between Algesal suractive and regular Algesal?

The inclusion of 'suractive' in the name typically indicates a specific formulation that includes two active ingredients. Official information shows that Algesal suractive contains Myrtecaine in addition to Diethylamine Salicylate. Myrtecaine is a local anaesthetic component that is often absent in single-component formulations.

---

Q: How quickly does Algesal suractive start to work?

Studies and official information indicate that the active component, Diethylamine Salicylate, is formulated to be absorbed rapidly into the skin. Regulatory documents note that the absorption is facilitated when the cream is massaged thoroughly into the skin, as directed in the administration instructions.

---

Q: How long does the effect of Algesal suractive typically last?

The duration of the product's symptomatic effect is reflected in the suggested frequency of use. Official administration instructions recommend applying the cream up to three times daily. This frequency is consistent with the regulatory administration schedule, which describes the use required to provide symptomatic effect.

---

Q: Can Algesal suractive be taken with common pain relievers like acetaminophen or ibuprofen?

Regulatory labeling cautions that using the cream alongside other non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, may potentially increase the risk of side effects. Acetaminophen (paracetamol) is not specifically listed in the documented contraindications or warnings for interaction.

---

Q: Is it normal to feel a tingling sensation when using Algesal suractive?

Officially documented reactions at the application site include a local burning sensation or redness. The product labeling does not specifically list 'tingling' as a potential side effect.

---

Q: Does Algesal suractive cause drowsiness or affect alertness?

The official safety information reports that potential systemic effects, especially if the cream is applied excessively or over large areas, include changes like agitation or confusion. Drowsiness is not specifically listed among the documented adverse events in the official product information.

---

Q: Can Algesal suractive be used on sensitive skin?

Safety notes in the product information advise users to avoid contact with sensitive areas of the skin. It is also noted that some people, particularly those with naturally sensitive skin, may experience some discomfort or temporary skin reactions.

---

Q: Is there a maximum age limit for using Algesal suractive?

Official documents indicate that the product is generally for use in adults, including the elderly population. The official product information does not specify a maximum age limit for using Algesal suractive.

---

Q: Is Algesal suractive safe to use during breastfeeding?

Regulatory documents define a specific restriction for this use. Official guidance states that Algesal suractive must not be used during breast-feeding.

---

Q: Where does the official evidence for Algesal suractive come from?

The regulatory basis for the product is supported by evidence derived from controlled clinical trials. These studies primarily focus on the effects of the topical salicylate component for localized, short-term musculoskeletal conditions.

---

Q: Do studies suggest Algesal suractive is for short-term use only?

Yes. Administration guidelines specify that the treatment is intended for a short duration. Regulatory documents advise against prolonged use without further professional guidance, and clinical research is typically limited to short-term durations.

---

Q: Does Algesal suractive contain menthol or camphor?

According to the official composition, Algesal suractive contains racemic camphor as an excipient (an inactive ingredient). The formula also includes a lavender composition, though menthol is not typically listed as an ingredient.

---

Q: Can Algesal suractive interact with blood pressure medication?

Regulatory labeling notes a possible interaction with certain medicines that affect fluid balance. Specifically, it mentions interaction potential with certain Diuretics (medicines that promote urination and salt excretion), such as Spironolactone.

---

Q: Is Algesal suractive considered a topical analgesic?

Yes. The product is officially described in regulatory documents as a topical analgesic and anti-inflammatory combination drug. This classification means it is used on the skin to help relieve localized pain and inflammation.

---

Q: Does Algesal suractive have a strong smell?

The official documents describe Algesal suractive as a cream with a slight scent of lavender. This odor comes from a lavender-based excipient, or inactive ingredient, included in the formulation.

---

Q: What kind of research has been done on Algesal suractive for muscle strains?

Research has focused on the use of the product's active topical salicylate component for adults with localized acute musculoskeletal conditions. This includes studies specifically examining conditions such as minor muscle strains and sprains.

---

Q: What packaging options is Algesal suractive available in (e.g., tube size)?

Regulatory packaging information indicates that Algesal suractive is commonly made available in a 40g tube size. Other packaging options may be available depending on the specific market.

---

Q: Does the application method affect how well Algesal suractive works?

Yes. Official administration instructions emphasize that the cream must be massaged thoroughly into the skin until it is fully absorbed. This procedural step is specified to support the appropriate delivery of the active components, as described in the product information.

---

Q: Is the 'suractive' part of the name related to how it is absorbed?

Official characteristics confirm that the 'suractive' formulation contains Myrtecaine, which plays a role in the drug's delivery. This component is described as facilitating the cream's penetration into the skin, which contributes to the localized therapeutic effect.

---

Q: Is the active substance in Algesal suractive a natural compound?

The active components of Algesal suractive are Diethylamine Salicylate and Myrtecaine. Official documents classify both of these substances as synthetic derivatives, meaning they are not derived directly from natural sources.

---

Q: Why do some people report feeling heat instead of coolness with Algesal suractive?

Officially documented adverse events include a local burning sensation at the application site. This is a temporary skin reaction reported in official product information.

---

Q: Is there any risk of addiction or dependence with Algesal suractive?

Algesal suractive is officially classified as a Topical Analgesic and Anti-inflammatory Combination Drug. Regulatory documents do not classify it as a controlled substance and do not list potential for addiction or dependence as a known risk.

---

Q: Does Algesal suractive come in different strengths?

Official regulatory data for Algesal suractive commonly describes the product as a fixed percentage formulation, often specified as 10%/1% w/w (Diethylamine Salicylate/Myrtecaine). Some formulations may have different active ingredient percentages depending on the specific product variant or regulatory authorization.

Storage and Disposal of Algesal suractive Cream

Official regulatory labeling dictates strict conditions to maintain the stability and safety of Algesal suractive Cream. The medicine must be stored at a temperature not above 25 C and must always be kept out of the sight and reach of children.

---

Stability and Handling

Requirement Category	Official Regulatory Statement
Maximum Temperature	Must be stored not above 25 C.
In-Use Shelf Life	Shelf life is 3 months after the container is first opened.

---

Disposal

When the product is no longer needed, it must not be disposed of in waste water or household waste. The official instruction is to ask the pharmacist how to dispose of the medicine to ensure environmental protection and proper pharmaceutical waste handling.